## PROTAC BRD9 Degrader-6

| Cat. No.:          | HY-153632   |       |          |  |  |
|--------------------|---|-------|----------|--|--|
| CAS No.:           | 2676211-62-2  |       |          |  |  |
| Molecular Formula: | C <sub>47</sub> H <sub>56</sub> N <sub>8</sub> O <sub>6</sub> |       |          |  |  |
| Molecular Weight:  | 829   |       |          |  |  |
| Target:            | PROTACs; Epigenetic Reader Domain                             |       |          |  |  |
| Pathway:           | PROTAC; Epigenetics   |       |          |  |  |
| Storage:           | Powder  | -20°C | 3 years  |  |  |
|                    |   | 4°C   | 2 years  |  |  |
|                    | In solvent  | -80°C | 6 months |  |  |
|                    |   | -20°C | 1 month  |  |  |

## SOLVENT & SOLUBILITY

| Preparing<br>Stock Solutions | Solvent Mass<br>Concentration   | 1 mg  | 5 mg                  | 10 mg      |           |
|------------------------------|---|---|-----------------------|------------|-----------|
|                              | 1 mM  | 1.2063 mL   | 6.0314 mL             | 12.0627 mL |           |
|                              |   | 5 mM  | 0.2413 mL             | 1.2063 mL  | 2.4125 mL |
|                              |   | 10 mM   | 0.1206 mL             | 0.6031 mL  | 1.2063 mL |
|                              | Please refer to the so  | lubility information to select the app                            | propriate solvent.    |            |           |
| In Vivo                      |   | one by one: 10% DMSO >> 90% (20<br>g/mL (3.02 mM); Clear solution | % SBE-β-CD in saline) |            |           |
|                              | one by one: 10% DMSO >> 90% corn oil<br>ng/mL (3.02 mM); Clear solution |   |                       |            |           |

| BIOLOGICAL ACTIV |   |
|------------------|---|
| Description      | PROTAC BRD9 Degrader-6 is a potent degrader of BRD9 (IC <sub>50</sub> =0.13 nM), can be used for research of BAF complex-related disorders <sup>[1]</sup> . |
| IC₅₀ & Target    | IC50: 0.13 nM (BRD9)  |

## REFERENCES

[1]. Ruppel Sabine K, et al. Preparation of substituted naphthyridines for treating BAF complex-related disorders. United States, US20210230190 A1. 2021-07-29.



**Product** Data Sheet

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA